On May 19, the Wall Street Journal revisited industry and patient relationships leading up to FDA approval of Sarepta’s eteplirsen. Chris Smith weighs in.
As hundreds of gene therapies advance through clinical trials, a genomic revolution is taking place before our eyes. Are we ready?
At this year’s J.P. Morgan Healthcare Conference, David Lapidus spoke with biopharma investors about our nation’s new leader. Here’s what happened.